Welch Foundation Works For Chemistry

One of the major private sources of funding for academic chemists in the United States is a foundation started at the bequest of Robert Alonzo Welch, a man who, ironically, didn't even finish elementary school. Despite his lack of formal education, Welch had an admiration for chemistry because of the discipline's contribution to his success (see story on page 27). Founded in 1954--two years after Welch's death--with $25 million allotted in his will, the Houston-based Welch Foundation now has as

Written byKathryn Fraser Dupont
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

One of the major private sources of funding for academic chemists in the United States is a foundation started at the bequest of Robert Alonzo Welch, a man who, ironically, didn't even finish elementary school. Despite his lack of formal education, Welch had an admiration for chemistry because of the discipline's contribution to his success (see story on page 27). Founded in 1954--two years after Welch's death--with $25 million allotted in his will, the Houston-based Welch Foundation now has assets of more than $280 million.

Norman Hackerman (Chairman), Distinguished Professor Emeritus of Chemistry and President Emeritus, William Marsh Rice University, Houston William O. Baker Chairman of the Board (retired), AT&T Bell Laboratories, Murray Hill, N.J. Elias J. Corey Professor of Chemistry, Harvard University, Cambridge, Mass. Peter B. Dervan Professor of Chemistry, California Institute of Technology, Pasadena Joseph L. Goldstein Professor and Chairman of Molecular Genetics, University of Texas Southwestern Medical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies